TuHURA CEO Dr. James Bianco looks at next steps for the TBS-2025 program and highlights the NPM1 mutated AML population that will be enrolled in the upcoming Phase Ib trial.
$HURA
#ImmunoOncology #CancerResearch #LifeSciences
youtube.com/shorts/Az3gD...

This #BreastCancerAwarenessMonth, FOCIS highlights immunology’s role in breast cancer research—from the tumor microenvironment to immune responses and new therapies—and the researchers advancing discoveries toward patient care.

#FOCIS #ImmunoOncology

🔬 How can single-domain antibodies improve tumor imaging?

In our latest interview, Brigitte Kerfelec discusses her research on mesothelin-targeting molecules, future cancer theranostics, and her journey as a scientist.

👉 Read the full interview: urls.fr/oOxWng

#CancerResearch #ImmunoOncology

To overcome tumor immune evasion, researchers engineered NK cells that target PD-L1, block NKG2A/HLA-E inhibitory signaling, and produce IL15 to improve antitumor activity, survival, and metabolic fitness.

#OpenAccess: doi.org/10.1038/s413...
#TumorImmunology #CellTherapy #ImmunoOncology

CEO Dr. James Bianco provides background to the patent announcement earlier today. He introduces TuHURA’s ADC program and explains how it can address immunosuppressive MDSCs and block the VISTA checkpoint inhibitor.
$HURA
#ImmunoOncology #CancerResearch #LifeSciences
youtu.be/rT1RLh6db8Y

If TuHURA is successful with its deep-seated tumor trial in Merkel cell carcinoma, it could expand IFx-2.0's addressable market by 30%. Join CEO Dr. James Bianco as he explains.
$HURA
#ImmunoOncology #CancerResearch #LifeSciences
youtube.com/shorts/vl5dw...

Tuhura Biosciences has a second program for IFx-2.0 in deep seated tumors. If successful, this approach could expand the population that may benefit from IFx. Join CEO Dr. James Bianco as he explains how it's done.
$HURA #ImmunoOncology #CancerResearch #LifeSciences
youtube.com/shorts/S1twF...

Meet genOway at the 85th Annual Meeting of the Japanese Cancer Association! 🇯🇵
Sept 24–26, Kyoto / Booth E-03
Featuring:
🔬 genO-panhCD3 — T-cell engager models
🔬 genO-hFcγR — Fc-mediated antibody function
Come talk models with our team!
#genOway #ImmunoOncology #JCA

Tuhura is developing IFx-2.0 in Merkel cell carcinoma. If it successfully shows synergy with checkpoint inhibitors, it could become the new standard of care. Join CEO James Bianco as he explains the program's objectives.
$HURA
#ImmunoOncology #CancerResearch #LifeSciences
youtube.com/shorts/erD62...

🖥️ Quantum computing may help advance precision #immunooncology.

A new quantum machine learning framework (Q-CHIPP) improved prediction of antigen presentation and immunotherapy response vs traditional methods.

▪️Tyler J. Alban, PhD

Learn more ➡️ https://ow.ly/mNEk50ZxyvT

Earlier today, TuHURA Biosciences announced that the FDA had cleared its IND for TBS-2025. Join CEO Dr. James A. Bianco, MD as he explains the rationale behind pursuing VISTA.
youtube.com/shorts/HJb6J...
$HURA #ImmunoOncology #CancerResearch #LifeSciences
ir.tuhurabio.com/news-events/...

September 11, 2026
👉 What if pancreatic cancer used… the blood-clotting system to protect itself from the immune system?
🙂 Another encouraging news from Groupe UIG.
Read: www.mountsinai.org/about/newsro...
#Cancer #PancreaticCancer #Immunotherapy #ImmunoOncology #Oncology #CancerResearch

11 septembre 2026
👉 Et si le cancer du pancréas utilisait… le système de coagulation pour se protéger du système immunitaire?
🙂 Une autre nouvelle encourageante du Groupe UIG.
Lire: www.mountsinai.org/about/newsro...
#Cancer #PancreaticCancer #Immunotherapy #ImmunoOncology #Oncology

In this blog we demonstrate how #bioinformatics analysis is beneficial for the assessment of novel immuno-oncology therapies. Read it now!
https://www.fiosgenomics.com/using-bioinformatics-to-assess-novel-immuno-oncology-therapies/
#oncology #immunooncology

September 9, 2026
👉 What if fewer CAR-T cells could sometimes deliver… greater efficacy?
🙂 Another encouraging news from Groupe UIG.
Read: medicalxpress.com/news/2026-09...
#CAR_T #CARtherapy #CancerResearch #Immunotherapy #ImmunoOncology

Myth vs. Fact in Small Cell #LungCancer! 💡
For #WRAD2026, Dr Nicolas Pourel breaks down modern #SCLC treatment: #IMRT/#VMAT, low side effects, dose escalation & #ImmunoOncology.
🎥 Watch: https://bit.ly/467gmhZ
#Radonc #LungCancer

September 5, 2026
👉 What if we could make cancer cells vulnerable to immunotherapy again?
🙂 Another encouraging news from Groupe UIG.
Read: lnkd.in/gwMarPZs
#CancerResearch #Immunotherapy #ImmunoOncology #PrecisionMedicine #Oncology #Biotech